RxDoctor Payments Data

Manova David, MD

Cardiovascular Disease · Canton, OHNPI 1184952913

Payments from drug & device makers

$877in general payments, 2019–2025

Across 18 payments — averaging $48.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$608
  • Johnson & Johnson$109
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$77
  • Novartis$29
  • Abiomed$24
  • E.r. Squibb & Sons, L.L.C.$17
  • plus $13 from 1 others

What the payments were for

  • Travel & lodging$43950%
  • Food & beverage$43850%

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$877 in reported general payments places this provider in the 35th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$170,362
Medicare patients
1,103
Services billed
2,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$89,378
EntrestoSacubitril/Valsartan52$58,747
JardianceEmpagliflozin88$56,237
XareltoRivaroxaban31$29,736
VascepaIcosapent Ethyl13$4,043
Metoprolol Succinate343$3,724
Icosapent Ethyl21$3,362
Ezetimibe187$3,305
Rosuvastatin Calcium245$2,451
Ranolazine ErRanolazine32$2,426
Atorvastatin Calcium321$2,319
Losartan Potassium183$1,135
Spironolactone140$679
Carvedilol89$675
SotalolSotalol Hcl45$656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$29$58,74752 claims
Johnson & JohnsonXarelto$109$29,73631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →